
Sapreme shares “unprecedented” preclinical data for Duchenne candidate
Sapreme Therapeutics has shared new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place in Denver, Colorado, US. SPM-2551 is intended to restore dystrophin to more than 15% of normal levels –… Read More
